Pep IQ
← Pep IQ
Substantial preclinical foundation. SS-31 (elamipretide, MTP-131, Bendavia) is a synthetic aromatic-cationic tetrapeptide of the Szeto-Schiller class, discovered serendipitously during opioid-receptor agonist peptide development. Mechanism: reversible binding to cardiolipin in the inner mitochondrial membrane, stabilising cristae structure, promoting cristae formation and curvature, and altering electrostatic environment. Earlier descriptions framed SS-31 as antioxidant; more recent work (Birk et al. 2013, Szeto 2014) clarified the cardiolipin-stabilisation mechanism. The compound decreases superoxide and H2O2 production specifically where overproduction results from dysfunctional mitochondria. Multiple animal models — heart failure, ischemia-reperfusion injury, acute kidney injury, doxorubicin cardiotoxicity, age-related mitochondrial dysfunction — support the protective effects.
Wellness/longevity community use is off-label and uncharted — the FDA approval is specifically for Barth syndrome, not anti-ageing. Where used off-label, doses extrapolate from MMPOWER trial parameters (0.01, 0.1, or 0.25 mg/kg/h IV in trial settings) but most community use is SubQ at lower doses without formal dose-finding. Pep IQ does not endorse community SS-31 protocols outside the approved Barth syndrome indication — the wellness use case has no published dose-response or safety profile, and the approved-indication trial framework involves IV dosing rather than community SubQ.
Substantial Phase 2/3 trial program. MMPOWER (Phase 1/2, n=36) — IV elamipretide in primary mitochondrial myopathy. TAZPOWER and the subsequent open-label extension supported FDA approval for Barth syndrome in September 2025 — significant improvement in cardiac stroke volume, cardiolipin levels, and reported fatigue. PROGRESS-HF examined heart failure with reduced ejection fraction. ReCLAIM trials in age-related macular degeneration. Reilly et al. 2021 (PMC 8282018) — randomised double-blind placebo-controlled trial in 39 healthy older adults (60–85 yrs) with poor mitochondrial function showed that a single dose of elamipretide improved in vivo skeletal muscle mitochondrial ATP production. The clinical evidence base is substantial across multiple mitochondrial disease indications.
FDA-approved as Forzinity (elamipretide) in September 2025 for Barth syndrome — a rare mitochondrial genetic disorder. This is the first member of the cardiolipin-binding peptide class to achieve regulatory approval. Manufactured by Stealth BioTherapeutics. Generally well-tolerated in trial populations; main adverse events were injection-site reactions. Other indications (heart failure, AMD, primary mitochondrial myopathy) explored in trials but did not lead to additional approvals — some trials missed primary endpoints despite the underlying mechanism evidence. Long-term safety in non-Barth populations is uncharted.
SS-31 (elamipretide/Forzinity) is a genuinely interesting compound with a novel mechanism (cardiolipin binding, mitochondrial cristae stabilisation), substantial preclinical foundation, and a fresh 2025 FDA approval for Barth syndrome — making it the first cardiolipin-targeted peptide to reach the clinic. But the approval is narrow; off-label wellness/longevity use has no validated dose-response or safety profile in healthy populations, and several adjacent trials (heart failure, AMD) missed primary endpoints despite the mechanistic plausibility. Pep IQ flags this honestly: legitimate compound with real Phase 3 evidence in its approved indication, but community use for general mitochondrial support is extrapolation, not validated medicine. The Reilly 2021 healthy-older-adult ATP-production data is the closest evidence we have for the wellness use case — single-dose, small sample, not a dosing protocol.
SS-31 was synthesised by Peter Schiller and Hazel Szeto — hence "Szeto-Schiller 31" — initially as part of a broader programme investigating aromatic-cationic peptides and their unusual ability to cross cell membranes without needing a carrier. What Szeto's team discovered, almost unexpectedly, was that the peptide didn't just cross cell membranes: it concentrated at the inner mitochondrial membrane at levels more than 1,000 times higher than the surrounding cell.
The reason for this selective accumulation is elegant chemistry. SS-31 carries two positively charged amino acids — D-arginine and lysine — which are electrostatically attracted to the highly negatively charged cardiolipin molecules embedded in the inner mitochondrial membrane. At the same time, aromatic amino acids in its structure (phenylalanine and dimethyltyrosine) shield those charges just enough to maintain cell permeability. The result is a peptide that finds its target with unusual precision.
Development was taken forward by Stealth BioTherapeutics, which pursued clinical trials under the name elamipretide and later Bendavia. In September 2025, the FDA granted accelerated approval for elamipretide (brand name Forzinity) for the treatment of Barth syndrome — making it the first approved mitochondria-targeted therapy in the United States. This milestone transformed SS-31 from a compelling research compound into a drug with real clinical standing.
To understand SS-31, you first need to understand cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is not passive structural material. It is the scaffolding on which the electron transport chain is built. It holds the respiratory complexes in their correct shape and orientation, enabling efficient transfer of electrons and, ultimately, the production of ATP — the molecule your cells use for energy.
When cardiolipin becomes oxidised — by ageing, disease, or chronic metabolic stress — the scaffolding warps. The respiratory complexes become less efficient, electron leakage increases, reactive oxygen species (ROS) multiply, and ATP production falters. This is mitochondrial dysfunction, and it sits upstream of an extraordinary range of conditions: heart failure, neurodegeneration, muscle wasting, kidney disease, and the broader process of biological ageing.
What makes SS-31 scientifically interesting is that it does not simply mop up free radicals — a blunt mechanism used by many antioxidant supplements with limited clinical results. Instead, it acts upstream: by stabilising the architecture that generates ROS in the first place, it addresses the root cause rather than the downstream symptom. Researchers describe this as a structural intervention rather than a scavenging one.
The following benefit areas reflect findings from preclinical models, human clinical trials, and expanded-access case studies. Evidence strength is rated honestly — a distinction this book maintains throughout.
SS-31 is, by the standards of the peptide world, unusually well-supported. It has a clearly understood mechanism, a substantial body of animal research, multiple completed human clinical trials, and as of September 2025, an FDA-approved indication. That is a combination most peptides discussed in wellness communities cannot match.
The fair question is: does the evidence for serious mitochondrial disease translate to meaningful benefit in healthy people seeking optimisation? The honest answer is that we don't know. The biological logic is coherent — mitochondrial function declines with age in everyone, not just those with genetic disorders — but logic is not data. No randomised controlled trial has examined SS-31 in healthy, non-diseased humans for longevity or performance purposes.
What we can say is that the safety profile from clinical trials is reassuring, the mechanism is genuinely novel, and the compound has now graduated from pure research curiosity to approved medicine. For a book about peptides and honesty, that deserves acknowledgment. For those considering self-experimentation: this is one of the more scientifically credible options in the mitochondrial category — and one where the risks, while real, appear manageable under careful conditions. Proceed with knowledge, not hype.